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Abstract
Background: Hepatocellular carcinoma (HCC) is a worldwide malignant liver tumor with high incidence in China.
Subchromosomal amplifications and deletions accounted for major genomic alterations occurred in HCC. Digital
karyotyping was an effective method for analyzing genome-wide chromosomal aberrations at high resolution.
Methods: A digital karyotyping library of HCC was constructed and 454 Genome Sequencer FLX System (Roche)
was applied in large scale sequencing of the library. Digital Karyotyping Data Viewer software was used to analyze
genomic amplifications and deletions. Genomic amplifications of genes detected by digital karyotyping were
examined by real-time quantitative PCR. The mRNA expression level of these genes in tumorous and paired
nontumorous tissues was also detected by real-time quantitative RT-PCR.
Results: A total of 821,252 genomic tags were obtained from the digital karyotyping library of HCC, with 529,162
tags (64%) mapped to unique loci of human genome. Multiple subchromosomal amplifications and deletions were
detected through analyzing the digital karyotyping data, among which the amplification of 7q21.3 drew our
special attention. Validation of genes harbored within amplicons at 7q21.3 locus revealed that genomic
amplification of SGCE, PEG10, DYNC1I1 and SLC25A13 occurred in 11 (21%), 11 (21%), 11 (21%) and 23 (44%) of the
52 HCC samples respectively. Furthermore, the mRNA expression level of SGCE, PEG10 and DYNC1I1 were
significantly up-regulated in tumorous liver tissues compared with corresponding nontumorous counterparts.
Conclusions: Our results indicated that subchromosomal region of 7q21.3 was amplified in HCC, and SGCE, PEG10
and DYNC1I1 were probable protooncogenes located within the 7q21.3 locus.
Background
Hepatocellular carcinoma (HCC) is one of the major
human malignant tumors worldwide. Accumulation of
genetic and epigenetic changes plays an important role
in the process of hepatocarcinogenesis. Chromosomal
aberration is among the most prevalent genetic altera-
tions observed in HCC [1]. Recurrent chromosomal
gains of 1q, 6p, 8q, 17q, and 20q, and losses of 1p, 4q,
5q, 6q, 8p, 9p, 10q, 13q, 16q, 17p, 19p, and 22q in HCC
have been documented in previous studies [2-7]. Explor-
ing cancer genome in great details always led to the
identification of cancer-associated genes (also referred
to as target genes) located within the amplified or
deleted chromosomal regions. For example, deletion at
1p36 locus in HCC was reported to be one of the com-
mon mechanisms for inactivation of RUNX3, a putative
tumor suppressor gene located within this region [8].
Elevated expression level of PTK2 and EIF3S3 genes in
HCC was demonstrated to be significantly correlated
with amplification of 8q23-q24, indicating a potential
role for these genes in progression of HCC [9].
Recent innovations on molecular genetic techniques
allowed investigators to perform genome-wide analysis of
chromosomal aberrations at high resolution. Among these
techniques, array-based comparative genomic hybridiza-
tion (aCGH), high-density single nucleotide polymorphism
(SNP) arrays and digital karyotyping have been proved to
be the most effective tools in discovering abnormal chro-
mosomal features [7,10,11]. Instead of generating analog
signal intensity in the array-based methods, digital karyo-
typing is characterized by providing direct, unbiased, pre-
cise and quantitative measurement of chromosomal
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Mb [12].
In the current study, digital karyotyping was applied to
detect chromosomal aberrations in HCC. We found that
the amplification at 7q21.3 locus may contribute to the
development or progression of HCC. Gains of 7q21
have been observed in tumors such as prostate cancer,
colorectal cancer and HCC [13-15]. Tsuji et al.h a s
identified PEG10 as a putative oncogene located within
the amplified 7q21 locus in HCC [16]. Our study high-
l i g h t e dt h a tm o r et a r g e tg e n e si n c l u d i n gS G C E ,
DYNC1I1, SLC25A13, as well as PEG10, were harbored
within the amplicons at 7q21.3 in HCC. Furthermore,
up-regulation of SGCE, DYNC1I1 and PEG10 genes
were also observed in HCC. These results indicated that
amplification of 7q21.3 may be involved in carcinogen-
esis of HCC, and SGCE, DYNC1I1 and PEG10 were
candidate oncogenes located within 7q21.3 locus.
Methods
Tissue samples
Clinical tumorous and corresponding non-tumorous
liver tissues were obtained from HBV-positive primary
HCC patients who underwent curative surgery. Speci-
mens were kept frozen in liquid nitrogen immediately to
avoid any degradation of RNA and/or DNA. Blood of
normal individuals was obtained from healthy people
who underwent regular physical examination. All sam-
ples were collected with informed consent and the study
was approved by the Institutional Human Subjects Pro-
tection Review Board.
Digital karyotyping
Genomic DNA was isolated from one tumorous liver tis-
sue using DNeasy kit (Qiagen) according to the manufac-
ture’s instruction. Then, 10 μg of genomic DNA was used
to generate digital karyotyping library as described by
Leary et al [17]. However, the concatemers of ditags were
not cloned into pZero because 454 Genome Sequencer
FLX System (Roche) was applied in large scale sequencing
in this study. Instead, the concatemers with adhesive ends
of CATG were ligated to a pair of modified adaptors A
+
and B
+ which provide priming regions for the following
emulsion PCR and 454 pyrosequencing. The original
Adaptor A and B provided by the GS FLX Standard DNA
Library Preparation Kit (Roche) were blunt-ended and
could not be ligated to concatemers directly. Thus, we
designed a modified Adaptor A
+ and B
+ with an extruding
end which was complementary to the adhesive end of con-
catemers. The sequences of Adaptor A
+ and B
+ were as
followings: Adaptor A
+ forward strand: 5’-CCA TCT CAT
CCC TGC GTG TCC CAT CTG TTC CCT CCC TGT
CTC AGAC T GC A TG - 3 ’;A d a p t o rA
+ reverse strand: 5’-
CAG TCT GAG ACA GGG AGG GAA CAG ATG GGA
CAC GCA GGG ATG AG-3’; Adaptor B
+ forward strand:
5’-Biotin-CCT ATC CCC TGT GTG CCT TGC CTA
TCC CCT GTT GCG TGT CTC AGA CTG CAT G-3’;
Adaptor B
+ reverse strand: 5’-CAG TCT GAG ACA CGC
AAC AGG GGA TAG GCA AGG CAC ACA GGG GA-
3’. The underlined basepairs were optional barcode
sequences. The following procedures were carried out
according to the original protocol [18], and sequencing
run was performed on 454 GS FLX instrument. The 21 bp
genomic tags were extracted using SAGE2000 software
(Invitrogen). The experimentally observed tags were
mapped to virtual tags on the genome and their relative
frequency was counted to detect genomic amplifications
and deletions using Digital Karyotyping Data Viewer soft-
ware http://cgap.nci.nih.gov/SAGE/DKViewHome. The
database of virtual genomic tags was established according
to sequences of NCBI Human Genome Assembly Build 37
(released on Aug 2009).
Quantitative PCR
Genomic DNAs were extracted from tumorous liver tis-
sues of 52 HCC patients and peripheral blood lymphocytes
of 52 normal individuals using DNeasy kit (Qiagen). PCR
reaction mixture of 25 μl was composed of 50 ng genomic
DNA, 12.5 μl SYBR Premix Ex Taq (TaKaRa), 250 nM of
each primer and appropriate volume of ddH2O. The ther-
mal cycles were performed on ABI Prism 7300 apparatus
(Applied Biosystems) with conditions of 95°C for 10 s, fol-
lowed by 40 cycles of 95°C for 5 s and 60°C for 30 s. Each
PCR reaction was performed in triplicate and threshold
cycle numbers were averaged. The primers (Table 1) were
designed using Primer 3 software http://frodo.wi.mit.edu/
primer3/. The repetitive element LINE-1, which is likely to
has an equivalent copy number in cancer and normal gen-
omes, was used as an endogenous control for normaliza-
tion of DNA content.
Quantitative reverse transcription-PCR (RT-PCR)
Total RNAs were extracted from 32 pairs of tumorous
and corresponding non-tumorous liver tissues using
TRIzol reagent (Invitrogen), and then treated with
Table 1 Primers used for real-time quantitative PCR
Genes Primers Product Size
LINE-1 F: AAAGCCGCTCAACTACATGG
R: TGCTTTGAATGCGTCCCAGAG
149 bp
SGCE F: CAGAGACCTTGCTTCCCTTG
R: CGTCTTATCAGCCACTGCAA
193 bp
DYNC1IC F: ATACAGGACACCCAGGCAAG
R: ACTTCTCGGACCATGTCAGG
138 bp
SLC25A13 F: AGGCAGAGCTGGCAAAATAA
R: TCATGCCTTTTTGATGTGGA
105 bp
PEG10 F: CCAGTTGTCATCCACCACAG
R: TGCAATTTTCCACAGACCAA
219 bp
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tion. The reverse transcription reactions and following
quantitative PCR reactions, as well as statistical analysis
were done as previously described [19]. GAPDH was
used as internal control for normalizing mRNA level.
The sequences of primers used for quantitative RT-PCR
were listed in Table 2.
Statistical analysis
Student’s t test and Bonferroni correction were applied in
the statistical analysis of quantitative PCR and RT-PCR
data.
Results
Digital karyotyping of HCC
We applied 454 pyrosequencing in the current study, and
obtained a total of 821,252 genomic tags from the digital
karyotyping library of HCC, among which 529,162 tags
could be mapped to unique loci of human genome (i.e. fil-
tered tags). By aligning these filtered tags across each chro-
mosome using Digital Karyotyping Data Viewer software
with a window size of 20, we identified multiple subchro-
mosomal regions of amplification (fold change ≥3) and
deletion (fold change ≤0.1) (Additional file 1). Among all
these chromosomal aberrations, gains of chromosome 7
were of most interest. As many as fifty amplicons with
sizes ranging from 287 bp to 212,814 bp were detected on
the q arm of chromosome 7, some of which harbored
known genes while some did not (Table 3). The amplified
subchromosomal region between 116,320,004 bp and
116,359,984 bp of 7q31 harbored MET gene, a well-
known oncogene involved in hepatocarcinogenesis [20,21].
The SGCE gene previously reported to be up-regulated in
HCC by our group [19], was identified to reside within an
amplicon at 94,187,248 bp–94,227,832 bp of 7q21.3.
According to the power calculation method developed by
Salani et al, a 3-fold amplification covering 38 kb could be
detected with a positive predictive value (PPV) ≥95% if
890,628 experimental tags were obtained [22]. Thus, with
821,252 tags available in this study, the PPV of detecting a
3-fold amplification of 40,584 bp which spans SGCE gene
was supposed to be approximately 95%. We also observed
that another two genes, DYNC1I1 and SLC25A13 located
closely to SGCE, were contained within the amplicons at
7q21.3. Gene expression profile analysis of HCC has
implied that SGCE and PEG10 harbored within 7q21.3
locus were putative tumor-associated genes [19]. Thus,
our further investigation was focused on 7q21.3 locus, try-
ing to find out more candidate protooncogenes within this
amplified subchromosomal region.
Genomic amplification of SGCE, PEG10, DYNC1I1 and
SLC25A13 in HCC
To validate genomic amplifications of SGCE, DYNC1I1
and SLC25A13 detected by digital karyotyping analysis,
real-time quantitative PCR was performed in 52 HCC
samples and 52 normal individuals. PEG10, a gene located
very closely to SGCE in a head-to-head manner, was also
selected for examination as a positive control, because
both amplification and up-regulation of PEG10 have been
observed in HCC [16,23]. The schematic illustration of
genes located within subchromosomal region of 7q21.3
(from 94,187,248 bp to 95,968,724 bp) was shown in
Figure 1. Amplification of genomic DNA was defined as
the DNA level of a HCC sample exceeded the mean plus 2
standard deviations of 52 normal individuals [24]. As
shown in Figure 2, genomic amplification of SGCE,
PEG10, DYNC1I1 and SLC25A13 was observed in 11
(21%), 11 (21%), 11 (21%) and 23 (44%) of the 52 HCC
samples respectively. In the cases of SGCE, PEG10, and
SLC25A13 genes, significant differences were observed
between HCC samples and normal individuals, with p <
0.05 after Bonferroni correction. However, the DYNC1I1
gene was likely to be a nominal one, with p value of 0.07
after Bonferroni correction (Additional File 2).
Up-regulated expression of SGCE, PEG10 and DYNC1I1 in
HCC
The transcript expression level of SGCE, PEG10,
DYNC1I1 and SLC25A13 genes in tumorous and paired
nontumorous tissues were examined in 32 HCC patients
by real-time quantitative RT-PCR. As shown in Figure 3
and Additional File 3, mRNA expression level of SGCE,
PEG10 and DYNC1I1 genes were up-regulated in tumor-
ous liver tissues compared with corresponding nontumor-
ous counterparts. However, no significant difference was
observed in expression level of SLC25A13 between tumor-
ous and nontumorous liver tissues (data not shown).
Taken together, these results suggested that SGCE, PEG10
and DYNC1I1 were putative oncogenes at the amplified
7q21.3 locus in HCC.
Discussion
In the present study, we applied 454 GS FLX, one of the
next-generation sequencing systems, in large-scale
Table 2 Primers used for real-time quantitative RT-PCR
Genes Primers Product Size
GAPDH F: ATGGGTGTGAACCATGAGAAG
R: AGTTGTCATGGATGACCTTGG
106 bp
SGCE F: ATGCAAACACCAGACATCCA
R: TCTGATGTGGCAAGTTCTGC
220 bp
DYNC1IC F: TGTGGTCCCCCGTGCATCCT
R: AGGGCGGATGCCCCCTCAAT
127 bp
SLC25A13 F: TGGCTGAGGCCCAGAGGCAG
R: GCTCCAGCAACAGAACCCAGACC
106 bp
PEG10 F: TCCTGTCTTCGCAGAGGAGT
R: TTCACTTCTGTGGGGATGGA
111 bp
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No. of amplicons Start Position (bp) End Position (bp) Amplification Size (bp) Known genes contained within amplicons
1 85669352 85675348 5996 –
2 90176250 90233199 56949 PFTK1
3 92170683 92181579 10896 –
4 92402830 92489679 86849 CDK6
5 92525776 92559603 33827 –
6 92621928 92628443 6515 –
7 94153659 94160414 6755 CASD1
8 94187248 94227832 40584 SGCE
9 95575453 95593279 17826 DYNC1I1
10 95625240 95626171 931 DYNC1I1
11 95626365 95634906 8541 DYNC1I1
12 95857177 95888724 31547 SLC25A13
13 95984342 95992052 7710 –
14 96016428 96091391 74963 –
15 96091675 96098719 7044 –
16 96223512 96436326 212814 SHFM1
17 96566511 96585224 18713 –
18 100008093 100031196 23103 ZCWPW1, MEPCE
19 100188936 100202216 13280 FBXO24, PCOLCE
20 100212010 100322730 110720 MOSPD3, TFR2, ACTL6B, GNB2, GIGYF1, POP7, EPO
21 100514082 100516140 2058 –
22 100594842 100615369 20527 MUC12
23 100619990 100633128 13138 MUC12
24 100899076 100900255 1179 –
25 100920401 100933959 13558 –
26 101043124 101046675 3551 EMID2
27 101047291 101056595 9304 EMID2
28 101542859 101587823 44964 CUX1
29 101708443 101725375 16932 CUX1
30 116320004 116359562 39558 MET
31 116359697 116359984 287 MET
32 116516633 116651559 134926 CAPZA2, ST7, ST7OT1, ST7OT4
33 116832388 116859422 27034 ST7, ST7OT3
34 116986284 117113342 127058 ASZ1
35 117258567 117275904 17337 CFTR
36 117301541 117312368 10827 CFTR
37 117348151 117357569 9418 CTTNBP2
38 117371511 117376667 5156 CTTNBP2
39 117487299 117511084 23785 CTTNBP2
40 117575700 117576160 460 –
41 117604668 117718500 113832 –
42 117727390 117773948 46558 –
43 117862904 117882935 20031 ANKRD7
44 117888893 117908976 20083 –
45 118228295 118274830 46535 –
46 118275399 118309895 34496 –
47 118442613 118473838 31225 –
48 118574464 118640670 66206 –
49 149702946 149746115 43169 –
50 153635222 153636533 1311 DPP6
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best of our knowledge, no digital karyotyping data of
HCC has been published in public. In most of the digital
karyotyping libraries of human brain and colon available
from public database http://cgap.nci.nih.gov/SAGE/
DKViewHome, tags matched to human genome
sequences accounted for 62~69% of total genomic tags
(Additional File 4). In our sequencing results, 64%
(529,162) of the total 821,252 genomic tags were
mapped tags, which was quite consistent with published
data. Sequentially aligning these tags along each chro-
mosome led to detection of subtle subchromosomal
alterations occurred in HCC, among which the amplifi-
cation of 7q21.3 drew our special attention.
The role of 7q21 amplification either in HCC cell lines
or in primary HCC tumors have been implicated in pre-
vious studies [16,23,25]. However, within the subchromo-
some region7q21.3, only PEG10 has been identified as a
potential target gene related to progressive development of
HCC [16,23]. Our study suggested that another two genes,
SGCE and DYNC1I1, may also be HCC-related protoon-
cogenes within the 7q21.3 locus. Genomic amplification of
PEG10, SGCE, DYNC1I1 and SLC25A13 were detected by
digital karyotyping analysis of HCC, and validated through
real-time quantitative PCR. Among 52 HCC samples we
examined, eleven (21%) of them showed genomic amplifi-
cation of SGCE, PEG10 and DYNC1I1 respectively, and
23 (44%) of them exhibited genomic amplification of
SLC25A13. Further examinations on mRNA expression
level of these genes found that SGCE, PEG10 and
DYNC1I1 were significantly up-regulated in HCC tumor-
ous tissues compared with the paired nontumorous coun-
terparts. Taken together, these findings indicated that in
addition to PEG10, SGCE and DYNC1I1 were likely to be
candidate targets for the 7q21.3 locus in HCC.
PEG10 has been identified as a putative target gene
for the amplification at 7q21, as well as a progression
related biomarker for HCC [16,23]. SGCE, the epsilon
member of sarcoglycan family, was demonstrated to be
involved in myoclonus-dystonia syndrome (MDS) which
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Page 5 of 8is characterized by rapid myoclonic jerks and dystonia
[26]. Recent studies shed light on a role SGCE may play
in tumors, as it was up-regulated in a parallel way with
PEG10 in both B-cell chronic lymphocytic leukemia and
HCC, and showed low or null microsatellite instability
in colorectal cancer [19,27,28]. However, since the func-
tion of SGCE and the mechanism of how it participate
in tumor progression remains unknown up to now, its
differential expression in HCC could only be regarded
as a potential tumor-related marker without any con-
crete function.
DYNC1I1 gene encoded dynein intermediate chains 1,
a component of cytoplasmic dynein complex, and parti-
cipated in recognizing, binding and transporting vesicles,
proteins, and RNAs et al [29,30]. DYNC1I1 was also
reported to be a reliable positive marker in testing bone
marrow stromal cells prepared for tissue engineering
and cell therapy [31]. Our study indicated DYNC1I1
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Figure 2 Real-time quantitative PCR validation of digital karyotyping data. Totally 52 normal individuals and 52 HCC samples were
examined for genomic DNA level of (A) SGCE, (B) PEG10, (C) DYNC1I1 and (D) SLC25A13 respectively by real-time quantitative PCR. The purple
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possible association between this gene and hepatocarci-
nogenesis. Further studies on DYNC1I1 as well as SGCE
are needed to explain the exact roles they may play in
HCC and/or other tumors.
Conclusions
In this study, we examined chromosomal aberrations of
HCC on a genome-wide scale and found that subchromo-
s o m a lr e g i o no f7 q 2 1 . 3w a samplified in HCC. Genomic
amplification of PEG10, SGCE, DYNC1I1 and SLC25A13
genes which located within the 7q21.3 locus were detected
in HCC, and up-regulated expression of genes was also
found in cases of PEG10, SGCE and DYNC1I1. These
results suggested that besides PEG10, SGCE and
DYNC1I1 may also be probable target genes in the sub-
chromosomal region of 7q21.3. Further studies are needed
to explore functional roles of PEG10, SGCE and DYNC1I1
genes might play in the initiation and/or progression of
HCC.
Additional material
Additional file 1: Subchromosomal regions of amplification and
deletion in HCC detected by digital karyotyping. Digital karyotyping
revealed that subchromosomal amplification (fold change ≥3) and
deletion (fold change ≤0.1) occurred in multiple chromosomes in HCC.
Additional file 2: Raw data of real-time quantitative PCR validation
for genomic DNA level of SGCE, PEG10, DYNC1I1 and SLC25A13
genes. Raw data of genomic DNA level of SGCE, PEG10, DYNC1I1 and
SLC25A13 genes in 52 normal individuals and 52 HCC samples were
presented in this file. Relative genomic DNA level of SGCE, PEG10,
DYNC1I1 and SLC25A13 genes were calculated according to the formula
2
Ct(LINE-1)-Ct(target gene). Student’s t test and Bonferroni correction were
applied in the statistical analysis of raw data.
Additional file 3: Raw data of real-time quantitative RT-PCR
detection for SGCE, PEG10 and DYNC1I1 genes. Raw data of SGCE,
PEG10 and DYNC1I1 gene expression level in 32 pairs of HCC and
corresponding nontumorous liver tissues determined by real-time
quantitative RT-PCR were presented in this file. Relative expression level
of DYNC1I1, SGCE and PEG10 genes were calculated according to the
formula 2
Ct(GAPDH)-Ct(target gene). Student’s t test and Bonferroni correction
were applied in the statistical analysis of raw data.
Additional file 4: Data summary of 23 digital karyotyping libraries
in public database. In the 23 digital karyotyping libraries available at
http://cgap.nci.nih.gov/SAGE/DKViewHome, percentage of tags matched
to human genome varied from 48% to 69%, while most of them were
between 62% and 69%.
Abbreviations
HCC: hepatocellular carcinoma; PEG10: paternally expressed 10; SGCE:
sarcoglycan, epsilon; DYNC1I1: dynein, cytoplasmic 1, intermediate chain 1;
SLC25A13: solute carrier family 25, member 13.
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